Literature DB >> 1804016

Activity of meropenem against antibiotic-resistant or infrequently encountered gram-negative bacilli.

J H Jorgensen1, L A Maher, A W Howell.   

Abstract

Meropenem was compared in vitro with imipenem as well as with several other contemporary beta-lactams, ciprofloxacin, and gentamicin against a group of highly antibiotic resistant members of the family Enterobacteriaceae and a collection of oxidase-positive and/or glucose-nonfermentative gram-negative bacilli. In this study, meropenem was more active than imipenem against isolates of Enterobacter, Klebsiella, Morganella, Providencia, Alcaligenes, Aeromonas, and Pasteurella.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1804016      PMCID： PMC245394          DOI： 10.1128/AAC.35.11.2410

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase.

Authors:  C E Smith; B S Tillman; A W Howell; R N Longfield; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Multicenter in vitro evaluation of SM-7338, a new carbapenem.

Authors:  R N Jones; K E Aldridge; S D Allen; A L Barry; P C Fuchs; E H Gerlach; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

3.  In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338.

Authors:  H C Neu; A Novelli; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 4.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  In-vitro studies of meropenem.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

6.  In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I.

Authors:  J R Edwards; P J Turner; C Wannop; E S Withnell; A J Grindey; K Nairn
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191
  6 in total
  11 in total

1.  Discordant carbapenem susceptibility in Methylobacterium species and its application as a method for phenotypic identification.

Authors:  G J Zaharatos; A Dascal; M A Miller
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

2.  Increasing incidence of nosocomial Chryseobacterium indologenes infections in Taiwan.

Authors:  P R Hsueh; L J Teng; P C Yang; S W Ho; W C Hsieh; K T Luh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-08       Impact factor: 3.267

Review 3.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods.

Authors:  J C Chang; P R Hsueh; J J Wu; S W Ho; W C Hsieh; K T Luh
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 5.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

6.  Distribution of cphA or related carbapenemase-encoding genes and production of carbapenemase activity in members of the genus Aeromonas.

Authors:  G M Rossolini; A Zanchi; A Chiesurin; G Amicosante; G Satta; P Guglielmetti
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing.

Authors:  S L Fraser; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

8.  Clinical and microbiological characteristics of Flavobacterium indologenes infections associated with indwelling devices.

Authors:  P R Hsueh; L J Teng; S W Ho; W C Hsieh; K T Luh
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

Review 9.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

10.  Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group.

Authors:  K P Klugman; R Dagan
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.